
Dogecoin Cash, Inc. Confirms Stock Dividend Record and Payment Dates; FINRA Publication Completed
MESQUITE, NV, May 06, 2025 (GLOBE NEWSWIRE) —
March 10, 2025 – Mesquite, NV – Dogecoin Cash, Inc. ($CBDS), a publicly traded leader in blockchain innovation, is excited to announce its strategic expansion into the rapidly growing meme coin
MESQUITE, NV – May 6, 2025 – Dogecoin Cash, Inc. (OTC: CBDS) today announced that its previously declared stock dividend distribution has been finalized and is now reflected in the Financial Industry Regulatory Authority's (FINRA) Daily List. The Company confirms that the payment date for this distribution is now set for May 9, 2025, while the record date remains November 25, 2024, as originally announced. The Company notes that no changes have been made to the amount or terms of the dividend.
As a Nevada corporation, and in accordance with general corporate law principles, the adjustment of a payment date—where the record date and distribution amount remain fixed—is considered a ministerial action. Therefore, the change has been authorized by management without requiring additional Board approval.
Item 8.01 – Other Events
Dogecoin Cash, Inc. (OTC: CBDS) received confirmation from the Financial Industry Regulatory Authority (FINRA) that its previously announced stock dividend, payable in a separate equity security, has been published on the FINRA Daily List today with a payable date of May 9, 2025.
As previously disclosed in public announcements, the dividend consists of a distribution of a new class of preferred stock to shareholders of record. For every 1,000 shares of common stock held on November 25, 2024, shareholders will receive one (1) share of unrestricted preferred stock of the issuer.
This preferred stock, designated as Series A Preferred pursuant to a Certificate of Designation filed with the Nevada Secretary of State on November 13, 2024, carries the right to receive, if and when declared by the Board of Directors, one (1) share of common stock annually per preferred share, provided the holder is of record as of November 25 of the applicable year. The stock is not convertible but may be redeemed at the Company's discretion on or before October 25, 2034, at a rate of ten (10) shares of common stock for each preferred share.
The symbol for Dogecoin Cash, Inc. common stock will remain CBDS until a new symbol is applied for. A trading symbol for the preferred shares has not yet been assigned. FINRA has indicated that no ex-dividend date will be established for this event.
Fractional shares will be rounded up to one whole share.
About Dogecoin Cash, Inc. (CBDS)
Dogecoin Cash, Inc. (OTCQB: CBDS) is a publicly traded company that owns and operates PrestoDoctor, a trusted leader in medical cannabis telemedicine. CBDS holds the first patented cannabis strain, Ecuadorian Sativa aka 'CTA', and a patented cannabis lozenge for treatment of hypertension. CBDS engages in cannabis product development and licensing, as well as blockchain innovation. The company is actively engaged in leveraging emerging digital assets, decentralized finance (DeFi) solutions, and blockchain technology to enhance its offerings and create new market opportunities.
Disclaimer:
Dogecoin Cash, Inc., and the DogeCoin Cash (DOG) token were inspired by the well-known cryptocurrency Dogecoin (DOGE); however, Dogecoin Cash, Inc. is not affiliated with, endorsed by, or associated with Dogecoin or its development team.
Forward-Looking Statements
Certain statements contained in this press release may constitute 'forward-looking statements.' Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as may be disclosed in the Company's filings. In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors, including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release, and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release. Such forward-looking statements are risks that are detailed on the Company's website and filings.
This press release contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially from those projected. For a detailed discussion of these risks and uncertainties, please refer to Dogecoin Cash, Inc.'s filings with the SEC.
Contact Information: [email protected]
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
3 hours ago
- Business Wire
WST截止日期:Rosen Law Firm敦促損失超過10萬美元的West Pharmaceutical Services, Inc. (NYSE: WST)股東與法律事務所聯絡以瞭解有關其權利的資訊
紐約--(BUSINESS WIRE)--(美國商業資訊)-- 全球投資人權益法律事務所Rosen Law Firm提醒投資人,一名股東代表在2023年2月16日至2025年2月12日期間購買West Pharmaceutical Services, Inc. (NYSE: WST)證券的投資人提起了集體訴訟。West將自身描述為一家「專注於注射藥物包裝元件、密封解決方案及輸送系統的醫療用品公司」。 如欲瞭解更多資訊,請遞交 表格 、向Phillip Kim律師 寄送電子郵件 ,或致電866-767-3653聯絡我們。 指控內容:Rosen Law Firm正在調查對West Pharmaceutical Services, Inc. (NYSE: WST)在其業務營運方面誤導投資人的指控。 起訴書指稱,在整個集體訴訟期內,被告做出了虛假和誤導性陳述及/或未揭露:(1)儘管聲稱對客戶需求有清晰預判,並將業務阻力歸咎於COVID相關產品的臨時性去庫存,但West實際上在其高利潤率的高價值產品(HVP)組合中持續經歷著顯著的去庫存現象;(2) West的SmartDose裝置雖被標榜為高利潤率的成長型產品,但由於營運效率不彰,對West的利潤率造成了嚴重稀釋;(3)這些利潤率壓力引發了高昂重整活動的風險,包括West退出與長期客戶簽署的持續血糖監測(CGM)合約;以及(4)由於上述原因,被告關於West的業務、營運和前景的正面陳述具有重大誤導性和/或缺乏合理依據。訴訟稱,當市場瞭解真實詳情後,投資人蒙受了損失。 現在怎麼辦:您可能有資格參與針對West Pharmaceutical Services, Inc.的集體訴訟。如果有股東希望擔任該集體訴訟的原告代表,則必須在2025年7月7日之前向法院提出申請。原告代表是指代表其他集體訴訟成員主導訴訟的當事人代表。您無需參與此案即有資格獲得追償。如果您選擇不採取任何行動,您也可以保持缺席集體訴訟成員的身分。如欲瞭解更多資訊,請點選 此處 。 所有代理均為勝訴後取酬。股東無需支付任何費用或開支。 關於Rosen Law Firm:與Rosen Law Firm不同,一些就此等事宜發表公告的法律事務所並不會實際提起證券集體訴訟。身為股東權益訴訟領域公認的領導者, Rosen Law Firm 一直致力於協助股東挽回損失、改善公司治理結構,並追究公司高階主管的違法行為責任。自成立以來,Rosen Law Firm已經為股東挽回了超過10億美元的損失。 請在LinkedIn: 、Twitter: 或Facebook: 上關注我們,以瞭解最新情況。 律師廣告。先前案例不保證可獲致類似結果。 免責聲明:本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用,煩請參照原文,原文版本乃唯一具法律效力之版本。


Business Wire
4 hours ago
- Business Wire
ELV Deadline: Rosen Law Firm Urges Elevance Health, Inc. (NYSE: ELV) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Elevance Health, Inc. (NYSE: ELV) Misled Investors Regarding its Business Operations. According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that, with the Medicaid redetermination process nearly complete, defendants represented to investors that they were closely monitoring cost trends associated with the redetermination process and that the premium rates Elevance was negotiating with states were sufficient to address the risk and cost profiles of those patients staying on Medicaid programs. While defendants acknowledged that Medicaid expenses were rising, they repeatedly assured investors that this was adequately reflected in Elevance's guidance for the year. These representations were materially false or misleading. In truth, the redeterminations were causing the acuity and utilization of Elevance's Medicaid members to rise significantly, as the members being removed from Medicaid programs were, on average, healthier than those who remained eligible for the programs. This shift was occurring to a degree that was not reflected in Elevance's rate negotiations with the states or in its financial guidance for 2024. When the true details entered the market, the lawsuit claims that investors suffered damages. What Now: You may be eligible to participate in the class action against Elevance Health, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by July 11, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome.


Business Insider
10 hours ago
- Business Insider
Morgan Stanley downgrades Itoham Yonekyu Holdings, Inc. (2296) to a Sell
In a report released today, Tomonobu Tsunoyama from Morgan Stanley downgraded Itoham Yonekyu Holdings, Inc. (2296 – Research Report) to a Sell, with a price target of Yen4,200.00. The company's shares closed yesterday at Yen4,890.00. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Tsunoyama is an analyst with an average return of -2.0% and a 25.00% success rate. Tsunoyama covers the Consumer Defensive sector, focusing on stocks such as Kewpie Corporation, Morinaga Milk Industry Co., Ltd., and Itoham Yonekyu Holdings, Inc.. The word on The Street in general, suggests a Hold analyst consensus rating for Itoham Yonekyu Holdings, Inc..